@Neuroscope_mp: 🚨 BREAKING Scientists may have...

🚨 BREAKING Scientists may have just cracked the code on Alzheimer's and Parkinson's — WITH ONE PILL.

A drug called Buntanetap was just published in a peer-reviewed journal with Phase 3 data.
Phase 3 means that we are on the verge of FDA approval.

It targets the ROOT CAUSE of both diseases simultaneously.

Here's what you need to know 🧵👇
#Alzheimers #Parkinsons

Tweet 2
Most people think Alzheimer's and Parkinson's are totally separate diseases.
They're not.

At autopsy, ~1 in 3 Alzheimer's patients have Lewy body (Parkinson's-type) protein in their brain.

And ~50% of Lewy body dementia patients have full Alzheimer's pathology too.

Same brain. Multiple diseases. Quietly overlapping. 🧠
That's called co-pathology — and it's why targeting just one protein may never be enough. 👇
#Dementia #Neurodegeneration

There are FOUR driving neurodegeneration:
🔴 Amyloid-β
🟠 Tau
🟡 Alpha-Synuclein
🟢 TDP-43
Every approved drug targets just one of these.
Buntanetap targets all four — simultaneously.
That's not an upgrade. That's a completely different philosophy. 👇
#Alzheimers #Buntanetap

How does it work?

Buntanetap doesn't clean up protein AFTER it's already damaged your brain.
It stops the proteins from being MADE in the first place.
It binds to mRNA — the blueprint — before toxic proteins are assembled.

Think of it as cutting the factory order, not cleaning up the mess. 🏭
#Parkinsons #Neurodegeneration

The clinical trial results are IN.
📊 Phase 2/3 Study:
• 351 patients
• 54 sites across the US
• 3 doses tested
• 12 weeks
Result: Statistically significant improvement in COGNITION in early Alzheimer's patients.
The 30mg dose showed +3.3 points on the ADAS-Cog11 scale vs placebo.
P < 0.001. 🔬

#Alzheimers #ClinicalTrials

But cognition is just one piece.
The biomarker data is where it gets REALLY interesting.

After treatment, researchers measured:
📉 Tau — REDUCED
📉 TDP-43 — REDUCED
📉 Neurofilament Light (NfL) — REDUCED
📉 Neuroinflammation markers (IL-6, IFN-γ) — REDUCED
This isn't just symptom relief.
This is hitting the BIOLOGY.

#Buntanetap #BrainHealth

Now for Parkinson's.
Buntanetap also completed a Phase 3 PD trial.
523 patients.
6 months.

Patients diagnosed 3+ years:
✅ Statistically significant motor improvements
✅ Cognitive decline HALTED overall
✅ Plasma tau REDUCED
Alpha-synuclein is the main villain in Parkinson's.
Buntanetap targets it too.
This is rare. 🧠

#Parkinsons #ClinicalTrials

What about safety? This is where Big Pharma drugs often fail.
Buntanetap:
✅ Well tolerated at ALL doses
✅ Safe in ApoE4 gene carriers (highest AD risk group)
✅ No major drug-related serious events
✅ Compatible with existing AD medications

And it's a PILL.
Not an IV infusion every two weeks.

That alone is a massive advantage. 💊
#Alzheimers #Parkinsons

The FDA is paying attention.

In October 2024: FDA cleared Annovis to proceed with Phase 3 trials in Alzheimer's.

In February 2026: An independent safety board (DSMB) reviewed the ongoing Phase 3 and said:
"No safety concerns. Continue as planned."

This is a green light from independent watchdogs. 🚦

#Buntanetap #Alzheimers

The pivotal Phase 3 is happening RIGHT NOW.
📍 760 patients
📍 83 locations across the US
📍 Only biomarker-confirmed early AD (pTau217+)
📍 18-month trial — symptomatic + disease-modifying readouts

⏱️ First results expected: Late 2026 / Early 2027
⏱️ Full disease-modification data: 2027–2028
This is the make-or-break moment. 🎯

#Buntanetap #Alzheimers

The pivotal Phase 3 is happening RIGHT NOW.
📍 760 patients
📍 83 locations across the US
📍 Only biomarker-confirmed early AD (pTau217+)
📍 18-month trial — symptomatic + disease-modifying readouts

⏱️ First results expected: Late 2026 / Early 2027
⏱️ Full disease-modification data: 2027–2028
This is the make-or-break moment. 🎯

#Buntanetap #Alzheimers

Compare this to approved Alzheimer's drugs.
Lecanemab & Donanemab (currently approved):
❌ IV infusion every 2 weeks
❌ Brain swelling risk (ARIA)
❌ Only targets amyloid
❌ ~$26,500/year

Buntanetap (if approved):
✅ Once-daily pill
✅ Targets 4 proteins
✅ No IV
✅ Potentially far cheaper

This is why researchers are excited.

#Buntanetap #Neurodegeneration

Important caveats — I won't hide them.
⚠️ The PD Phase 3 missed its primary endpoint overall (benefit was in subgroups only)
⚠️ The AD Phase 2/3 was only 12 weeks
⚠️ Disease modification is NOT YET proven — Phase 3 is the real test
⚠️ No FDA approval yet

The science is promising.
But Phase 3 data (2026-2028) decides everything.
This is not a guaranteed win. Stay skeptical AND curious.
#Buntanetap #ClinicalTrials

So here's the bottom line:
Buntanetap is:
✅ Oral, once daily
✅ Published in peer-reviewed journals (Nature, 2026)
✅ Phase 3 safety cleared
✅ Targeting 4 proteins no other approved drug touches simultaneously

The pivotal results come in 2026–2028.
If it works, this changes everything.
Follow for updates.
Share if someone you love has AD or PD. 🧠❤️

[Full source list in reply 👇]
#Alzheimers #Parkinsons #Buntanetap

Buntanetap is exciting because it targets multiple overlapping proteins that drive most cases.

I wrote about this bigger shift ... Parkinson’s as many different diseases here.
Copathology needs to be addressed.
neuroscope.substack.com/p/a-new-era-fo…